Abstract
Background: Hydrochlorothiazide (HCTZ) is commonly used to treat black patients with hypertension. To avoid the metabolic disturbances associated with high‐dose HCTZ, blood pressure control may be achieved by combining low doses with another antihypertensive.
Hypothesis: The study was undertaken to assess the tolerability and antihypertensive dose‐response efficacy of telmisartan and HCTZ and their combination in black patients with mild to moderate hypertension (mean supine blood pressure 140/95‐200/114 mmHg).
Methods: Following a 4–week, single‐blind, placebo run‐in period, 222 black patients were randomized to once‐daily treatment with one of 20 different double‐blind combinations of telmisartan (0, 20, 40, 80, 160 mg) and HCTZ (0, 6.25, 12.5, 25 mg) for 8 weeks. Blood pressure was measured at baseline and after 2, 4, and 8 weeks.
Results: Telmisartan 80 mg/HCTZ 12.5 mg reduced supine trough diastolic blood pressure (DBP)—primary efficacy parameter—by 13.3 mmHg, and supine trough systolic blood pressure (SBP) by 21.5 mmHg. These reductions represented benefits of 13.7/8.7 mmHg over telmisartan 80 mg and 12.3/8.1 mmHg over HCTZ 12.5 mg(p<0.01). Telmisartan 40 mg/HCTZ 12.5 mg reduced supine trough SBP/DBP by 14.3/10.0 mmHg, amounting to 12.3/3.3 mmHg more than telmisartan 40 mg and 5.1/4.8 mmHg more than HCTZ 12.5 mg, This reached significance for the comparisons with telmisartan 40 mg for SBP and HCTZ 12.5 mg for DBP (p≤0.05). A response surface analysis and therapeutic response rates confirmed the additive antihypertensive effects of telmisartan and HCTZ. All treatments were well tolerated, with side‐effect profiles comparable with placebo. Adverse events were mainly transient and of mild to moderate severity.
Conclusions: Telmisartan 80 mg combined with HCTZ 12.5 mg is effective and well tolerated in black patients with mild to moderate hypertension, providing greater antihypertensive activity than the corresponding monotherapies.
Keywords: telmisartan, hydrochlorothiazide, hypertension, AT1 receptor antagonist, combination therapy, blacks
Full Text
The Full Text of this article is available as a PDF (647.2 KB).
References
- 1. The sixth report of the Joint National Committee on Prevention , Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–2446 [DOI] [PubMed] [Google Scholar]
- 2. Saunders E: Hypertension in minorities: Blacks. Am J Hypertens 1995; 8: 115S–119S [DOI] [PubMed] [Google Scholar]
- 3. Weinberger MH: Diuretics and their side effects. Dilemma in the treatment of hypertension. Hypertension 1988; 11 (suppl II): 16–20 [DOI] [PubMed] [Google Scholar]
- 4. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents : Single‐drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914–921 [DOI] [PubMed] [Google Scholar]
- 5. Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, Anderson RJ, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents : Age‐race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. J Am Med Assoc 1998; 280: 1168–1172 [DOI] [PubMed] [Google Scholar]
- 6. Weinberger MH: Blood pressure and metabolic responses to hydrochlorothiazide, captopril and the combination in black and white mild to moderate hypertensive patients. J Cardiovasc Pharmacol 1985; 7: 552–555 [DOI] [PubMed] [Google Scholar]
- 7. MacKay JH, Arcura KB, Goldberg AI, Snapinn SM, Sweet CS: Losartan and low‐dose hydrochlorothiazide in patients with essential hypertension: A double‐blind, placebo‐controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278–285 [PubMed] [Google Scholar]
- 8. Kochar M, Guthrie R, Triscari J, Kassler‐Taub K, Reeves RA: Matrix study of irbesartan with hydrochlorothiazide in mild to moderate hypertension. Am J Hypertens 1999; 12: 797–805 [DOI] [PubMed] [Google Scholar]
- 9. Andrén L, Weiner L, Svensson A, Hansson L: Enalapril with either a “very low” or “low” dose of hydrochlorothiazide is equally effective in essential hypertension: A double‐blind trial in 100 hypertensive patients. J Hypertens 1983; 1 (suppl 2): 384–386 [Google Scholar]
- 10. Morgan DB, Davidson C: Hypokalemia and diuretics: An analysis of publications. Br Med J 1980; 280: 905–908 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Skoularigis J, Strugo V, Chopamba A, Setekge S, Sareli P: Low dose hydrochlorothiazide (12.5–25 mg daily) as monotherapy in black patients with mild to moderate hypertension: Assessment by ambulatory blood pressure monitoring. Am J Hypertens 1995; 8: 1046–1050 [DOI] [PubMed] [Google Scholar]
- 12. Weinberger MH: Angiotensin converting enzyme inhibitors enhance the antihypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects. J Cardiovasc Pharmacol 1989; 13 (suppl 3): S1–4 [DOI] [PubMed] [Google Scholar]
- 13. Neutel JM, Smith DHG: Dose‐response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15: 206–217 [Google Scholar]
- 14. Smith DHG, Neutel JM, Morgenstern P: Once‐daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998; 15: 229–240 [Google Scholar]
- 15. Neutel JM, Frishman WH, Oparil S, Papademitriou V, Guthrie G: Comparison of telmisartan with lisinopril in patients with mild to moderate hypertension. Am J Ther 1999; 6: 161–166 [DOI] [PubMed] [Google Scholar]
- 16. Lacourcière Y, Lenis J, Orchard R, Lewanczuk R, Houde M, Pesant Y, Wright J, Wilson T, Martin K, on behalf of the Canadian Telmisartan Study Group : A comparison of the efficacies and duration of action of the angiotensin II receptor blocker telmisartan and amlodipine. Blood Press Monit 1998; 3: 295–302 [PubMed] [Google Scholar]
- 17. Mallion JM, Siché JP, Lacourcière Y, and the Telmisartan Blood Pressure Monitoring Group : ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild to moderate hypertension. J Hum Hypertens 1999; 13: 657–664 [DOI] [PubMed] [Google Scholar]
- 18. Ellis ML, Patterson JH: A new class of antihypertensive therapy: Angiotensin II receptor antagonists. Pharmacotherapy 1996; 16: 849–860 [PubMed] [Google Scholar]
- 19. Johnston CI: Angiotensin II receptor antagonists: Focus on losartan. Lancet 1995; 346: 1403–1407 [DOI] [PubMed] [Google Scholar]
- 20. Hall WD: Pathophysiology of hypertension in blacks. Am J Hypertens 1990; 3: 366S–371S [PubMed] [Google Scholar]
- 21. McGill J, Reilly PA: Identifying effective dose combinations of an AH antagonist and a diuretic in patients with hypertension. J Hum Hypertens 1999; 13 (suppl 3): S10 [Google Scholar]
- 22. Hung HMJ, Chi GYH, Lipicky RJ: Testing for the existence of a desirable dose combination. Biometrics 1993; 49: 85–94 [PubMed] [Google Scholar]
- 23. Laska EM, Meisner MJ: Testing whether an identified treatment is best. Biometrics 1989; 45: 1139–1151 [PubMed] [Google Scholar]
- 24. Phillips JA, Cairns V, Koch GG: The analysis of a multiple‐dose combination‐drug clinical trial using response surface methodology. J Biopharm Stat 1992; 2: 49–67 [DOI] [PubMed] [Google Scholar]
- 25. Mallion JM, Goldberg AI: Global efficacy and tolerability of losartan, an angiotensin II subtype 1‐receptor antagonist, in the treatment of hypertension. Blood Press 1996; 5 (suppl 2): 82–86 [PubMed] [Google Scholar]
- 26. Goldberg A, Sweet C: Efficacy and safety of losartan. Can J Cardiol 1995; 11 (suppl F): 27F–32F [PubMed] [Google Scholar]
- 27. Kaplan NM: Continued advances in antihypertensive therapy. Cardiovasc Rev Rep 1992; 13: 43–48 [Google Scholar]
- 28. Levine B: Effect of eprosartan and enalapril in the treatment of black hypertensive patients: Subgroup analysis of a 26‐week, double‐blind, multicentre study. Curr Med Res Opin 1999; 15: 25–32 [DOI] [PubMed] [Google Scholar]
- 29. Hypertension Detection and Follow‐up Program Cooperative Group : Five‐year findings of the Hypertension Detection and Follow‐up Program: Mortality by race‐sex and blood pressure level. A further analysis. J Community Health 1984; 9: 314–327 [PubMed] [Google Scholar]
- 30. Ooi WL, Budner NS, Cohen H, Madhavan S, Alderman MH: Impact of race on treatment response and cardiovascular disease among hypertensives. Hypertension 1989; 14: 227–234 [DOI] [PubMed] [Google Scholar]